1. Home
  2. ULH vs ANNX Comparison

ULH vs ANNX Comparison

Compare ULH & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Logistics Holdings Inc.

ULH

Universal Logistics Holdings Inc.

HOLD

Current Price

$17.04

Market Cap

400.0M

Sector

Industrials

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.25

Market Cap

334.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ULH
ANNX
Founded
1932
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
400.0M
334.1M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
ULH
ANNX
Price
$17.04
$5.25
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$17.00
$16.50
AVG Volume (30 Days)
61.4K
3.0M
Earning Date
02-05-2026
11-10-2025
Dividend Yield
2.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,638,101,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.78
$1.29
52 Week High
$47.42
$5.73

Technical Indicators

Market Signals
Indicator
ULH
ANNX
Relative Strength Index (RSI) 56.20 59.16
Support Level $15.79 $4.55
Resistance Level $17.39 $5.73
Average True Range (ATR) 0.97 0.35
MACD 0.14 -0.03
Stochastic Oscillator 84.17 60.34

Price Performance

Historical Comparison
ULH
ANNX

About ULH Universal Logistics Holdings Inc.

Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The company reports into four segments namely trucking, intermodal, company-managed brokerage, and contract logistics. The majority of the revenue is earned from the contract logistics segment.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: